Whitehawk Therapeutics (WHWK) Gross Profit (2021 - 2025)

Whitehawk Therapeutics (WHWK) has 5 years of Gross Profit data on file, last reported at $6.4 million in Q1 2025.

• On a quarterly basis, Gross Profit rose 35.82% year-over-year to $6.4 million in Q1 2025; TTM through Dec 2025 was $6.4 million, a 72.19% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, down 72.19% from the prior year.
• Gross Profit for Q1 2025 stood at $6.4 million, down from $6.4 million in the prior quarter.
• Over the last five years, Gross Profit for WHWK reached as high as $14.0 million in Q4 2021 and fell as low as $2.1 million in Q1 2022.
• Historically, Gross Profit has averaged $5.6 million across 5 years, with a median of $5.4 million in 2023.
• Across the five-year window, Gross Profit slumped 64.25% in 2022 and jumped 150.85% in 2023, its largest moves.
• Year by year, Gross Profit stood at $14.0 million in 2021, then slumped by 64.25% to $5.0 million in 2022, then grew by 7.87% to $5.4 million in 2023, then increased by 19.45% to $6.4 million in 2024, then slipped by 0.99% to $6.4 million in 2025.
• Per Business Quant data, the three most recent Gross Profit figures were $6.4 million in Q1 2025, $6.4 million in Q4 2024, and $6.4 million in Q3 2024.